Valeant Pharmaceuticals International, Inc. today announced a series of leadership and organizational changes.
Effective August 8, 2016, Christina Ackermann has been named Executive Vice President and General Counsel of Valeant, reporting directly to Joseph C. Papa. Ms. Ackermann is an experienced counselor with deep pharmaceutical industry experience. For the past 14 years, she has served in various legal roles at the Novartis group of companies, most recently as Senior Vice President, General Counsel for Alcon, where she was responsible for the Legal, Intellectual Property and Compliance functions. Ms. Ackermann succeeds Robert Chai-Onn, who will be leaving Valeant after a transition period.
“We are fortunate to have Christina as our new General Counsel,” said Joe Papa. “Her qualifications and track record of dealing successfully with complex legal and compliance issues make her an ideal addition to the Valeant team, and I am confident that she will provide sound counsel and support to our business leaders around the world.”
“This is a very exciting time to be joining Valeant,” said Ms. Ackermann. “The company has many attractive opportunities as well as some challenges, which I look forward to working through with my colleagues. I am very pleased to have this opportunity to assist Joe and the rest of the team with the company’s transformation.”
Scott Hirsch Joins Valeant as Senior Vice President, Business Strategy and Communications
Valeant also announced that Scott Hirsch has joined the company as Senior Vice President, Business Strategy and Communications. Mr. Hirsch is a seasoned investment professional with a deep knowledge of the specialty pharmaceutical industry. He joins Valeant from Citadel Investment Group, where he oversaw equity investments and risk management decisions within the Health Care sector at Surveyor Capital. Earlier in his career, he was in the investment banking group of Credit Suisse as the Lead Equity Research Analyst covering Specialty Pharmaceuticals and Generics.
“I have known Scott for many years – both as an investor and an analyst – and I think he is an extraordinary addition to the Valeant team,” said Joseph C. Papa, chief executive officer of Valeant. “His insights into the sector and knowledge of Valeant’s businesses will be invaluable as we take further action to stabilize and transform the company.”
Scott Hirsch stated, “Valeant has some of the best assets in specialty pharma and a tremendous amount of untapped potential. I share Joe’s vision for the future of Valeant, and I am excited to work with him and the rest of the management team to create value for our stakeholders.”
Valeant also announced today that Laurie Little, who has led the Investor Relations and Public Relations functions for the past nine years, will be leaving the company in the coming months and that Pavel Mirovsky, President and General Manager, Europe will retire later this year.
“As we develop our strategic plan to create the new Valeant, we are adding top talent to the leadership team, promoting high-performing leaders from within, and creating new structures and processes to help strengthen operations as we move forward,” said Joseph C. Papa. “I extend my sincere appreciation to Rob Chai-Onn, Laurie Little and Pavel Mirovsky for their efforts on behalf of Valeant over many years, and we all wish them well in their future endeavors.”
Senior Leaders Take on Expanded Roles; Executive Committee Realigned to Include Leaders from Key Business and Functional Areas
The company also announced today a series of changes and promotions that expand the roles of key senior leaders, align the company’s organizational structure with its go-forward strategy and position the company for sustained growth.
In addition, Mr. Papa has expanded the Executive Committee, adding leaders from several key business and functional areas of the company, all of whom will report directly to him:
Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.
Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.
There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.